The effect of intralesional injection of glucantime with low-level laser therapy in the treatment of acute cutaneous leishmaniasis

Comparing the effect of two therapeutical methods including intralesional injection of glucantime alone and with low-level laser therapy in the treatment of acute cutaneous leishmaniasis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N14

Enrollment

Registered

2020-12-07

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Control group: Patients in the first group are treated only with intralesional injection of glucantime(Sanofi Company). The patient receives a topical injection of glucantime 0.5 to 1.

So that all around the lesion (one millimeter ring around it) becomes white. Topical treatment with injectable glucantime lasts up to 8 weeks. Intervention 2: Intervention group: Patients in the secon

So that all around the lesion (one-millimeter ring around it) becomes white. Topical treatment with injectable glucantime lasts up to 8 weeks. In addition, patients were treated by a low-level laser u

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Proven diagnosis of acute rural cutaneous leishmaniasis by testing The number of lesions of less than 4 The disease course of fewer than 100 days Lesion size of less than 3 cm No lesion on the eyelid (less than 2 cm from the eyelid) Aged over 5 years old No lesion on cartilage or joint and face

Exclusion criteria

Exclusion criteria: Presence of sporotrichoid lesions or satellite lesions Taking immunosuppressive drugs during the last 6 months The history of receiving topical or systemic anti-leishmaniasis treatment in the past month Lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Lesion healing. Timepoint: The first to twelfth weeks from the beginning of the intervention. Method of measurement: Observation.;Lesion area. Timepoint: The first to twelfth weeks from the beginning of the intervention. Method of measurement: Ruler.	—

Secondary

Measure	Time frame
Recurrence of the lesion. Timepoint: Three months and six months after the intervention. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Asilian

Esfahan University of Medical Sciences

asilian@med.mui.ac.ir+98 31 3335 9797

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026